Data from the AFFIRM and RESTORE trials were used to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) effects of TYSABRI
Study description:The RESTORE study was an exploratory, randomized, multicenter, partially blinded, parallel-group study that assessed the timing of pharmacokinetic and pharmacodynamic changes based upon TYSABRI initiation and interruption in 175 patients with RMS
Study limitations:
aThe blue, dashed line indicates total lymphocyte counts prior to TYSABRI treatment in the AFFIRM TYSABRI treatment arm.
Study was funded by Biogen.